Cutaneous toxicities associated with amivantamab in patients with non-small cell lung cancer: A systematic review
收藏Mendeley Data2026-04-18 收录
官方服务：
资源简介：
Supplementary material (table S1, Table S2 and Figure S1).
应用场景：
创建时间：
2026-02-04
相关数据集
Comparison of different types of quinolones and cephalosporins usage as exposure towards the risk of developing hypoglycemia emergency (event).
Comparison of different types of quinolones and cephalosporins usage as exposure towards the risk of developing hypoglycemia emergency (event).
Figshare2022-04-04 更新60
Baseline characteristics.
Background Retrospective evidence indicated potential survival benefit of consolidative stereotactic radiotherapy (SRT) in patients with metastatic driver mutation-negative non-small cell lung cancer
NIAID Data Ecosystem30
DataSheet13_Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.zip
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations. Howeve
NIAID Data Ecosystem20
Concerted Suppression of STAT3 and GSK3β Is Involved in Growth Inhibition of Non-Small Cell Lung Cancer by Xanthatin
Xanthatin, a sesquiterpene lactone purified from Xanthium strumarium L., possesses prominent anticancer activity. We found that disruption of GSK3β activity was essential for xanthatin to exert its an
NIAID Data Ecosystem50
Dataset from Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.
The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dos
NIAID Data Ecosystem30
